HGSI Ponders Next Move After Rebuffing GSK's $2.6B Offer

As analysts weighed in on the unsolicited offer by GlaxoSmithKline plc (GSK) to purchase Human Genome Sciences Inc. (HGSI) for $13 per share in cash, or $2.6 billion, shares (NASDAQ:HGSI) of the biotech reached $14.61 before closing at $14.17 for a gain of 97.6 percent.